Discover
BI-1808 / BioInvent; Keytruda (pembrolizumab) / Merck (MSD)BioInvent Submits a CTA for a Phase I/IIa trial of BI-1808, A First-in-class Anti-TNFR2 Antibody for the Treatment of Patients With Solid Tumors and CTCL (PRNewswire) - Jun 30, 2020 - "BioInvent International AB…announces it has submitted a clinical trial application (CTA) to begin a Phase I/IIa, first-in-human study of BI-1808, a monoclonal antibody to tumor necrosis factor receptor 2 (TNFR2), as a single agent and in combination with KEYTRUDA® (pembrolizumab) for the treatment of solid tumors and cutaneous T-cell lymphoma (CTCL)…The study will explore the safety, tolerability, and potential signs of efficacy of BI-1808 as a single agent and in combination with KEYTRUDA® in patients with ovarian cancer, non-small cell lung cancer and cutaneous T cell lymphoma….It will be conducted at several sites across Europe and the U.S. and is expected to enroll approximately 120 patients."
Keytruda (pembrolizumab) / Merck (MSD); Lenvima (lenvatinib) / Eisai, Merck (MSD)Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) (clinicaltrials.gov) - Jul 2, 2020 - P2; N=600; Active, not recruiting; Sponsor: Merck Sharp & Dohme Corp.; N=180 --> 600; Trial completion date: Apr 2022 --> Feb 2024; Trial primary completion date: Apr 2022 --> Feb 2024
Zepzelca (lurbinectedin) / PharmaMar, JazzZepzelca: Newly added patent in Orange Book (Orange Book) - Jul 3, 2020 - Expiry on December 13, 2024
